Fate Therapeutics
FATE
164 hedge funds and large institutions have $402M invested in Fate Therapeutics in 2024 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 43 increasing their positions, 59 reducing their positions, and 36 closing their positions.
583% more call options, than puts
Call options by funds: $239K | Put options by funds: $35K
0% more capital invested
Capital invested by funds: $401M → $402M (+$482K)
6.66% less ownership
Funds ownership: 107.43% → 100.77% (-6.7%)
10% less funds holding
Funds holding: 182 → 164 (-18)
27% less repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 59
44% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 36
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$8.03M |
| 2 |
SCM
Superstring Capital Management
New York
|
+$3.77M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.9M |
| 4 |
Goldman Sachs
New York
|
+$1.85M |
| 5 |
BlackRock
New York
|
+$1.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$12.7M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$4.4M |
| 3 |
AG
Artal Group
Luxembourg
|
-$3.39M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$2.85M |
| 5 |
D.E. Shaw & Co
New York
|
-$2.72M |
FATE Hedge Fund Activity: Q3 2024 in Review
164 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q3 2024, worth a combined $402M — up 0.12% from $401M a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of FATE and 20 opened new positions — a net loss of 16 holders — while 59 trimmed existing stakes and 43 added.
The largest buyer was Woodline Partners, adding an estimated $8.03M. The largest seller was Boxer Capital, cutting an estimated $12.7M.
- 164 institutional investors held Fate Therapeutics (FATE) as of Q3 2024, down from 182 in Q2 2024.
- Funds reported $402M of Fate Therapeutics stock for Q3 2024, up 0.12% quarter-over-quarter.
- 20 funds opened new Fate Therapeutics positions in Q3 2024 and 36 closed out, a net change of -16 holders.
- The largest Fate Therapeutics buyer in Q3 2024 was Woodline Partners, an estimated $8.03M added.
- The largest Fate Therapeutics seller in Q3 2024 was Boxer Capital, an estimated $12.7M sold.
Based on aggregated 13F filings for Q3 2024.